Unlocking the future of cancer treatment
CAR-T cell therapy at Mayo Clinic
In the field of cancer treatment, Chimeric Antigen Receptor T-cell (CAR-T) therapy stands out as a unique novel management approach for patients with certain types of blood cancers. Providing access to this groundbreaking therapy can create cancer survivors.
What is CAR-T cell therapy?
CAR-T cell therapy is a revolutionary form of immunotherapy that harnesses the power of a patient's own immune system to fight cancer. This personalised treatment involves collecting a patient's immune T-cells which may not be effective by themselves, genetically modifying them to produce chimeric antigen receptors (CARs) that can better recognise and attack cancer cells, multiplying these retrained T-cells, and then infusing these enhanced cells back into the patient's body. This process has shown success in treating certain blood cancers, including B-cell acute lymphoblastic leukemia, various types of non-Hodgkin's lymphoma, and multiple myeloma. Large international clinical trials as well as available real-world data have shown unprecedented benefit for patients with CAR-T cell therapy when no other standard treatment options may be available.
Benefits for insurers and brokers
By offering access to CAR-T cell therapy, insurers and brokers can provide their members with a cutting-edge treatment option that has shown significant improvement in outcomes for cancer patients with even end-stage disease in some cases. This not only enhances the value of your insurance plans but also demonstrates a commitment to providing the best possible care for your members.
Why choose Mayo Clinic for CAR-T cell therapy?
Mayo Clinic's CAR-T Cell Therapy Program is certified to prescribe all available CAR-T cell products and offers a comprehensive, patient-centered approach to care. Patients at Mayo Clinic benefit from the expertise of a multidisciplinary team of specialists who collaborate with an integrated approach to provide the best possible outcomes. Mayo Clinic's commitment to offering all available cutting-edge treatment approaches, medical discovery, and clinical trials, ensures that
patients have access to the latest and most effective treatments.
Sikander Ailawadhi, M.D., Hematologist-Oncologist at Mayo Clinic, and the Lead for Cancer International, emphasises the transformative potential of CAR-T cell therapy, “CAR-T cell therapy offers hope to patients whose cancers have not responded to conventional treatments and even in such situations where no other conventional treatments exist.”
Mayo Clinic's CAR-T Cell
Therapy Program is certified
to prescribe all available
CAR-T cell products and offers
a comprehensive, patient-centred
approach to care
Comprehensive care and support
Mayo Clinic's CAR-T Cell Therapy Program includes a thorough evaluation process, personalised treatment plans, and ongoing support for patients and their families. The programme also offers financial coverage options and assistance with insurance approvals, ensuring a seamless experience for international patients.
Conclusion
As the field of cancer treatment continues to advance, CAR-T cell therapy represents a significant breakthrough in the fight against blood cancers with potential future offerings for certain solid organ cancers as well. By collaborating with Mayo Clinic, private medical insurers and insurance brokers can offer their members access to this life-changing therapy, providing hope and improved outcomes for patients worldwide.
Mayo Clinic is a nonprofit organisation dedicated to clinical practice, education, and research. It provides comprehensive, whole-person care and is renowned for solving complex medical challenges. With a history of innovation spanning more than 150 years, Mayo Clinic consistently ranks among the top healthcare providers globally.
For more information about CAR-T cell therapy at Mayo Clinic, visit Mayo Clinic's CAR-T Cell Therapy Program
www.mayoclinic.org/departmentscenters/car-t-cell-therapy-program.
For more information about providing your covered members with access to Mayo Clinic, visit International Contracting and Payer Relations
www.mayoclinic.org/intlcontracting.
Dr Sikander Ailawadhi, M.D. Hematologist-Oncologist, Mayo Clinic
Sikander Ailawadhi, M.D., is a Hematologist-Oncologist at Mayo Clinic in Jacksonville, Florida. He specialises in the treatment of blood cancers, particularly multiple myeloma, and is an expert in CAR-T cell therapy. Dr Ailawadhi is dedicated to advancing cancer treatment through innovative therapies and clinical trials.
November 2024
Issue
This month we look at affinity partnerships and ask if online travel agencies are the perfect partners for insurers; we cover the trends around cruising in the Mediterranean; we delve into the specifics of the Austrian healthcare system; plus we examine international healthcare and technology, asking how far can technology go.
Editorial Team
The Editorial Team updates the ITIJ website daily, and works on features for the print edition. With expert industry knowledge and years of experience in writing about complex travel insurance issues, the Editorial Team is ready to investigate and report on the topics that matter most to ITIJ's readers.
February 2025
Issue
Offering readers a deep dive into the issues facing providers and payers of healthcare services around the world. Cost containment, international patient department development, the role of AI in healthcare delivery and more.
